Patent: 9,952,300
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,952,300
Title: | Dynamic contrast enhanced MRI method and agents for the assessment of the macromolecular transport within pathologic tissues |
Abstract: | The present invention generally relates to paramagnetic contrast agents and a Dynamic Contrast Enhanced-MRI method for the non-invasive estimation of the delivery of a macromolecular anticancer drug or pro-drug within pathological tissues and, especially, in solid tumors and for the optimization of anticancer therapies. |
Inventor(s): | Giavazzi; Raffaella (Milan, IT), Maiocchi; Alessandro (Monza, IT), Moschetta; Michele (Trani, IT), Valbusa; Giovanni (Verbania, IT) |
Assignee: | BRACCO IMAGING S.P.A. (Milan, IT) |
Application Number: | 14/382,585 |
Patent Claims: | see list of patent claims |
Details for Patent 9,952,300
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-03-05 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-03-05 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-03-05 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2032-03-05 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2032-03-05 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2032-03-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |